Insmed reported $542.22M in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Cytokinetics USD 247.21M 868.77M Mar/2026
DBV Technologies USD 0 0 Mar/2025
Gilead Sciences USD 20.86B 1.27B Mar/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Insmed USD 542.22M 1.25M Mar/2026
Novartis USD 29.59B 5.35B Dec/2025
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025